Search Within


Applied Filters:
Showing 1-25 of 25 results for "Y0000317" within Papers
Aulma R Parker et al.
Molecular cancer therapeutics, 9(9), 2558-2567 (2010-09-03)
Taxane and platinum drugs are important agents in the treatment of cancer and have shown activity against a variety of tumors, including ovarian, breast, and lung cancer, either as single agents or in combination with other chemotherapy drugs. However, a
Lakshmi Pendyala et al.
Cancer chemotherapy and pharmacology, 51(5), 376-384 (2003-04-19)
BNP7787 (disodium 2,2'-dithio-bis-ethane sulfonate) was evaluated in a phase I clinical trial with paclitaxel and cisplatin to assess the safety and potential efficacy for preventing or reducing cisplatin- and paclitaxel-induced toxicities. During this trial the effects of BNP7787 administration on
F H Hausheer et al.
Cancer chemotherapy and pharmacology, 67(2), 381-391 (2010-05-05)
Previous studies from our laboratory have identified a role for gamma-glutamyl transpeptidase (GGT) in BNP7787 (disodium 2,2'-dithio-bis ethane sulfonate, dimesna, Tavocept™)-mediated cisplatin nephroprotection. Dekant has proposed that gamma-glutamyl transpeptidase (GGT), aminopeptidase N (APN) and cysteine-conjugate-β-lyase (CCBL) comprise a multi-enzyme pathway
Maartje M C Bastings et al.
BMC biotechnology, 8, 76-76 (2008-10-03)
Expression systems based on self-cleavable intein domains allow the generation of recombinant proteins with a C-terminal thioester. This uniquely reactive C-terminus can be used in native chemical ligation reactions to introduce synthetic groups or to immobilize proteins on surfaces and
Antonius A Miller et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 3(10), 1159-1165 (2008-10-02)
We investigated dose-dense docetaxel and cisplatin in patients with measurable non-small cell lung cancer in a randomized phase II study without [A] or with [B] a putative chemoprotective agent, BNP7787. Chemotherapy-naive patients with stage IIIB (effusion) or IV, performance status
E Boven et al.
British journal of cancer, 92(9), 1636-1643 (2005-04-21)
BNP7787 (disodium 2,2'-dithio-bis-ethane sulphonate; Tavocept) is a novel agent developed to protect against cisplatin (cis-diammine-dichloroplatinum(II))-associated chronic toxicities. In this study, we determined the recommended dose of BNP7787 when preceding a fixed dose of cisplatin, the pharmacokinetics (PKs) and the possible
Miranda Verschraagen et al.
Biochemical pharmacology, 68(3), 493-502 (2004-07-10)
Disodium 2,2'-dithio-bis-ethane sulfonate (BNP7787) is under investigation as a potential new chemoprotector against cisplatin-induced nephrotoxicity. The selective protection of BNP7787 appears to arise from the preferential uptake of the drug in the kidneys, where BNP7787 would undergo intracellular conversion into
R Todd Reilly
IDrugs : the investigational drugs journal, 7(1), 64-69 (2004-01-20)
BioNumerik Pharmacology Inc, Baxter Oncology GmbH (formerly ASTA Medica AG) and Grelan Pharmaceutical Co Ltd are developing BNP-7787 for the potential reduction of toxicity associated with cisplatin and carboplatin treatment in cancer patients.
Frederick H Hausheer et al.
Cancer chemotherapy and pharmacology, 52 Suppl 1, S3-15 (2003-06-24)
Any approach applied to drug discovery and development by the medical community and pharmaceutical industry has a direct impact on the future availability of improved, novel, and curative therapies for patients with cancer. By definition, drug discovery is a complex
M J Cutler et al.
Journal of clinical pharmacology, 52(4), 530-542 (2011-04-21)
Mesna and its dimer, dimesna, are coadministered for mitigation of ifosfamide- and cisplatin-induced toxicities, respectively. Dimesna is selectively reduced to mesna in the kidney, producing its protective effects. In vitro screens of uptake and efflux transporters revealed saturable uptake by
The effect of cytoprotective agents in platinum anticancer therapy.
Michael A Jakupec et al.
Metal ions in biological systems, 42, 179-208 (2004-06-23)
Miranda Verschraagen et al.
Journal of pharmaceutical sciences, 92(5), 1040-1050 (2003-04-25)
Sensitive, accurate, and precise assays are described to determine BNP7787 (disodium 2,2'-dithio-bis-ethane sulfonate) and its metabolite mesna (sodium 2-mercaptoethane sulfonate) simultaneously in plasma and tissue by micro-high-performance liquid chromatography (HPLC) with dual electrochemical detection. After separation of BNP7787 and mesna
Supercomputer-designed drug protects against chemotherapy toxicity.
K Senior
The Lancet. Oncology, 1, 198-198 (2002-03-22)
Miranda Verschraagen et al.
Cancer chemotherapy and pharmacology, 51(6), 525-529 (2003-05-17)
BNP7787 (2',2'-dithio-bis-ethane sulfonate sodium) is a novel protector against cisplatin-induced toxicities. The pharmacokinetics of BNP7787 and its metabolite mesna were investigated in plasma and ascites of a cancer patient. We also evaluated potential pharmacokinetic interactions between BNP7787 and cisplatin. BNP7787
Miranda Verschraagen et al.
Clinical pharmacology and therapeutics, 74(2), 157-169 (2003-08-02)
BNP7787 (disodium 2,2'-dithio-bis-ethane sulfonate) is currently undergoing development as a chemoprotective agent to prevent common and serious cisplatin-induced side effects. In the kidneys, intestine, and liver, BNP7787 is believed to undergo intracellular conversion into 2-mercaptoethane sulfonate (mesna), which can locally
Dakshine Shanmugarajah et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 877(10), 857-866 (2009-03-13)
BNP7787 (disodium 2,2'-dithio-bis ethane sulfonate; Tavocept) is a novel water-soluble investigational agent that is undergoing clinical development for prevention and mitigation of cisplatin-induced nephrotoxicity. BNP7787 is a disulfide that undergoes thiol-disulfide exchange reactions in vivo with physiological thiols. Mesna-disulfide heteroconjugates
F H Hausheer et al.
Journal of pharmaceutical sciences, 100(9), 3977-3984 (2011-02-24)
BNP7787, an investigational drug undergoing global Phase III development, appears to have potential advantages over other cytoprotective compounds that have been evaluated for preventing and mitigating cisplatin-induced nephrotoxicity. Herein, we characterized the in vitro accumulation of BNP7787 in human renal
Noriyuki Masuda et al.
Cancer chemotherapy and pharmacology, 67(3), 533-542 (2010-05-18)
We conducted a phase I trial of BNP7787 (disodium 2,2'-dithio-bis-ethane sulfonate, Tavocept™), a novel chemoprotective and antitumor enhancing agent administered in combination with paclitaxel and cisplatin. The primary aim was to determine a safe and potentially efficacious BNP7787 dose for
Frederick H Hausheer et al.
Cancer chemotherapy and pharmacology, 65(5), 941-951 (2009-08-29)
The mechanisms for cisplatin-induced renal cell injury have been the focus of intense investigation for many years with a view to provide a more effective and convenient form of nephroprotection. BNP7787 (disodium 2,2'-dithio-bis ethane sulfonate; dimesna, Tavocept), is a water-soluble
Miranda Verschraagen et al.
Cancer chemotherapy and pharmacology, 51(6), 499-504 (2003-04-26)
BNP7787 is a new chemoprotective agent presently under clinical investigation to protect against cisplatin-induced toxicities, especially nephrotoxicity and neurotoxicity. In the kidneys BNP7787 is postulated to undergo selective conversion into mesna, which can locally detoxify cisplatin. The reactivity of cisplatin
M Verschraagen et al.
British journal of cancer, 90(8), 1654-1659 (2004-04-15)
In preclinical studies, BNP7787 (disodium 2,2'-dithio-bis-ethane sulphonate), the disulphide form of mesna, has demonstrated selective protection against cisplatin-induced nephrotoxicity due to conversion into mesna inactivating toxic platinum species. Mesna (sodium 2-mercapto ethane sulphonate), however, can affect the antitumour activity of
M P Goren et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 4(10), 2313-2320 (1998-10-31)
Although mesna has been used for more than a decade to reduce the incidence of hemorrhagic cystitis induced by ifosfamide and cyclophosphamide, the disposition of i.v. and oral mesna has not been adequately described. To obtain accurate bioavailability data for
M Verschraagen et al.
Journal of chromatography. B, Biomedical sciences and applications, 753(2), 293-302 (2001-05-04)
A sensitive and accurate assay was developed and validated to determine BNP7787 (dimesna), a new protector against cisplatin-induced toxicities, and its metabolite mesna in plasma and urine of patients. Both analytes were measured as mesna in deproteinized plasma or in
Ying-Sing Li et al.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 59(8), 1791-1798 (2003-05-09)
Raman, and infrared spectra of mesna and dimesna have been collected in the present spectroscopic studies. Based on the group frequencies, relative intensities and Raman depolarization measurements, some vibrational assignments have been suggested. For both mesna and dimesna, at least
E Boven et al.
European journal of cancer (Oxford, England : 1990), 38(8), 1148-1156 (2002-05-15)
BNP7787 (2',2'-dithio-bis-ethane sulphonate sodium), a water-soluble disulphide, is chemically and mechanistically different from other sulphur-containing chemoprotective agents. Presently, BNP7787 is under investigation for its protective properties with regard to the side-effects of platinum compounds. In this study, we evaluated BNP7787
Page 1 of 1